News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cipher Pharmaceuticals (DND.TO) Receives FDA Response to CIP-TRAMADOL ER Appeal



2/1/2008 3:18:00 PM

MISSISSAUGA, ON, Feb. 1 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding its appeal of the Agency's Approvable Letter for CIP-TRAMADOL ER, Cipher's extended-release formulation of tramadol. In the response, the Acting Director of the Office of Drug Evaluation II, Center for Drug Evaluation and Research supported the Division's approvable action.

Read at Canada NewsWire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES